Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  bicalutamide
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-19 of 19 for your search:
Start Over
Hormone Therapy in Treating Men With Stage IV Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: Adult
Sponsor: NCI, Other
Protocol IDs: CDR0000064184, SWOG-9346, CAN-NCIC-PR8, CALGB-9594, ECOG-S9346, EORTC-30985, CAN-NCIC-JPR8, INT-0162, PR8, NCT00002651
Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 79
Sponsor: Other
Protocol IDs: JCOG0401, C000000026, NCT00138008
Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: CDR0000571528, MRC-RADICALS-PR10, ISRCTN40814031, EUDRACT-2006-000205-34, EU-20767, PR13, NCT00541047
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG 0815, CDR0000648194, NCI-2011-01948, NCT00936390
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG-0924, CDR0000701128, NCI-2011-02674, NCT01368588
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S1216, SWOG-S1216, NCI-2012-02876, NCT01809691
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: PROS0065, NCI-2015-00089, P30CA124435, NCT02346253
Degarelix Neo-Adjuvant Radical Prostatectomy Trial
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: DEG_PRE-OP_001, Degarelix Pre-Op, NCT01674270
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2013-083, NCI-2014-00212, 1311012529, P30CA022453, NCT02058706
A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2013.117, HUM00082715, NCT02059213
A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: J1408, NA_00092522, NCT02146937
Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UC-0105/1304, 2013-001652-36, NCT02299999
Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Fudan BR2015-17, NCT02348281
AR-inhibitor Bicalutamide in Treating Patients With TNBC
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: JinlingH-001, NCT02353988
Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: Under 80
Sponsor: Other
Protocol IDs: CDR0000639358, CLCC-RHOMUS, CRAD001 C2486, INCA-RECF0921, EUDRACT-2007-003620-38, RHOMUS, NCT00943956
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11D.243, 2011-32, NCT01420250
Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
Phase: No phase specified
Type: Treatment
Status: Active
Age: 70 and over
Sponsor: Other
Protocol IDs: 10-625-A, NCT01342367
Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CCRO025, NCT02064036
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 21 to 85
Sponsor: Other
Protocol IDs: 23842, NCT02366494
Start Over